Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More


While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.

In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George Golumbeski, who was profiled in Xconomy this week. Golumbeski rose through the ranks to top positions at both companies, eventually earning a reputation for... Read more »

Reprints | Share:          E-mail
UNDERWRITERS AND PARTNERS

          

          

            

Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National, Novartis, Parkinson's Disease, Abbvie, Biotech, UC Berkeley, Microbiome, Pancreatic Cancer, Crispr, Chemotherapy, Life Sciences, Martin Shkreli, Wu-tang Clan, Autoimmune Disorders, Regenerative Medicine, Celgene, Bristol-myers Squibb, Roche, Sanofi, UC San Diego, European Medicines Agency, Jennifer Doudna, National Cancer Institute, Inflammation, Starboard Value, Eli Lilly, Gene Editing, University of North Carolina at Chapel Hill, Giovanni Caforio, Atezolizumab, Pembrolizumab, Regeneron Pharmaceuticals, National blog main, New York blog main, New York top stories, Seattle blog main, Seattle top stories, Boston blog main, National top stories, San Francisco blog main, San Francisco top stories, Texas blog main, Texas top stories, Boston top stories, Detroit blog main, Detroit top stories, Raleigh-Durham blog main, Xconomy, San Diego blog main, San Diego top stories, Wisconsin blog main, Wisconsin top stories, Johnson & Johnson, Glaucoma, Opioids, Boulder/Denver blog main, Boulder/Denver top stories, Deerfield Management, Aerie Pharmaceuticals, seres Therapeutics, Raleigh-Durham top stories, NVS, Moderna, C4 Therapeutics, Zafgen, Cancer Immunotherapy, Indiana blog main, Indiana top stories, Dupilumab, President Trump, Erlotinib, Surrozen, Drug Prices, National Institutes of Health (NIH, Novartis Institutes for BioMedical Research, Cytokinetics, Axovant, Karyopharm Therapeutics, Selinexor, InventisBio, Cancer Drugs, BioNtech, Voyager Therapeutics, Arsanis, Principia Biopharma, Gemcitabine, Latanoprost, Ozanimod, Non-Small Cell Lung Cancer, George Golumbeski, Companion Diagnostic, Atopic Dermatitis, He Jiankui, Norman Sharpless, Ned Sharpless, Adam Crystal, Gastric Cancer, Nab-paclitaxel, Netarsudil, Ramucirumab, Tenaya Therapeutics, Triple-negative Breast Cancer, Whittemore Tingley, X4 Pharmacecuticals, Golumbeski

Source:  https://xconomy.com/national/2019/03/15/bio-roundup-golumbeskis-legacy-crispr-moratorium-rebate-week-more/